GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.63 (-0.94%)
As of 3:06PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close67.35
Bid66.54 x 900
Ask66.55 x 800
Day's Range66.11 - 67.36
52 Week Range60.89 - 71.19
Avg. Volume9,799,627
Market Cap84.411B
Beta (5Y Monthly)1.26
PE Ratio (TTM)15.81
Earnings DateN/A
Forward Dividend & Yield2.72 (4.03%)
Ex-Dividend DateMar 11, 2020
1y Target EstN/A
  • Are Investors Undervaluing Gilead Sciences, Inc. (NASDAQ:GILD) By 23%?
    Simply Wall St.

    Are Investors Undervaluing Gilead Sciences, Inc. (NASDAQ:GILD) By 23%?

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Gilead Sciences, Inc...

  • Gilead poaches Bristol-Myers Squibb site head in continuing exec team remake
    American City Business Journals

    Gilead poaches Bristol-Myers Squibb site head in continuing exec team remake

    Gilead, under new CEO Daniel O'Day, hires BMS's Redwood City site head, who has been focused on why immunotherapy drugs work in some cancers on some people and not others.

  • Is Gilead Stock A Buy As It Takes Aim At The Deadly Coronavirus?
    Investor's Business Daily

    Is Gilead Stock A Buy As It Takes Aim At The Deadly Coronavirus?

    Gilead is one of the biggest biotech companies. But recent news and earnings have been mixed. So, is GILD stock a buy right now? Read on for a full analysis.

  • The Wuhan Virus and Research-Focused Biotech Companies

    The Wuhan Virus and Research-Focused Biotech Companies

    With the spread of the new coronavirus from Wuhan, investors should consider investing in smaller biotech and pharma players Continue reading...


    Vertex Is the Top Big Biotech, According to Citi. 3 More Stocks It Says to Buy.

    In a note out Thursday evening, Citi Research analyst Mohit Bansal put his money on (VRTX) the up-and-comer that analysts can’t say enough good things about. “VRTX could be the next entry in the $100B market cap club,” Bansal wrote. (VRTX) (ticker: VRTX) tops Bansal’s ranking of large-cap biotech names, a list that includes (AMGN)(AMGN), (REGN)(REGN), (GILD)(GILD), and (BIIB)(BIIB), among others.

  • Investopedia

    Gilead Sciences Stock at Cusp of New Uptrend

    Gilead Sciences stock has completed a massive double bottom, setting the stage for an uptrend that catches market watchers off guard.

  • Reuters

    Gilead drug prevents type of coronavirus in monkeys; raises hope for China trials

    An experimental Gilead Sciences antiviral drug prevented disease and reduced the severity of symptoms in monkeys infected with Middle East Respiratory Syndrome (MERS), an infection closely related to the fast-spreading coronavirus that originated in China, a study published on Thursday found. The results, reported in Proceedings of the National Academy of Sciences, raise hope that the drug, remdesivir, currently in clinical trials in China, might be effective against the new virus that has infected some 60,000 people globally, and killed more than 1,300, mostly in China.

  • Reuters

    Results from Chinese drug trials for coronavirus due in weeks -expert

    Chinese scientists are testing two antiviral drugs against the new coronavirus and preliminary clinical trial results are weeks away, the co-chair of a World Health Organization (WHO) meeting said on Wednesday. Dr. Marie-Paule Kieny, a former WHO virologist, co-chaired the two-day, closed-door research forum in Geneva of more than 300 scientists and researchers, including some who took part virtually from China and Taiwan. "The Chinese colleagues are very eager to participate in protocols which are being defined so that all the clinical trials are done according to the same standards and are looking towards the same outcome," she told a news conference.

  • China Keeps Experts Waiting; Conference Canceled: Virus Update

    China Keeps Experts Waiting; Conference Canceled: Virus Update

    (Bloomberg) -- Warm weather may not slow down the spread of the coronavirus, said a top U.S. health official, counter to a theory put forward by President Donald Trump. U.S. disease experts are still waiting to hear whether they’ll be allowed by China to go to the outbreak’s front lines.Mobile World Congress, the premier mobile-industry conference, was canceled by its organizers over concerns about the spread of the deadly pathogen. In China, President Xi Jinping said the country would meet its economic goals while battling the coronavirus that has now claimed 1,115 lives. U.S. Federal Reserve Chairman Jerome Powell said it would take time to measure the impact of the outbreak.Bloomberg is tracking the outbreak on the terminal and online.Key DevelopmentsChina death toll at 1,113; confirmed China cases at 44,653See a breakdown of virus cases hereVirus-hit firm tells staff: Welcome back, wash your handsJapan reports 39 more cases aboard cruise shipEurope to Step Up Crisis Preparations (3:47 p.m. NY)The European Union is preparing for potential medical shortages and the risk of travel restrictions that could disrupt the bloc’s border-free zone.During an emergency meeting scheduled in Brussels on Thursday, EU health ministers plan to ask the bloc’s executive arm to assess the consequences of global health threats like the coronavirus on the availability of medicine and the security of supply chains, according to a draft of a joint communique seen by Bloomberg. The draft is still subject to changes.The document acknowledges that “measures regarding travel” could be necessary if the situation deteriorates, while ministers will vow to protect the “free movement” of people -- a key pillar of EU integration -- in such case.Similar temporary measures have been applied in the past to limit the flow of asylum seekers from poorer to richer EU members.Mnuchin: More Data Needed to Assess Impact (3:17 p.m. NY)U.S. Treasury Secretary Steven Mnuchin said Wednesday that two to four more weeks of economic data are needed to forecast the impact of coronavirus.Mnuchin also told a Senate Finance Committee hearing that implementation of the first phase of a U.S. trade deal with China is being slowed by the virus. On Tuesday, White House National Security Advisor Robert O’Brien said agricultural purchases under the deal may not be as large as the Trump administration had hoped due to coronavirus.China Keeps U.S. Experts Waiting (2:39 p.m. NY)Top U.S. health experts seeking to join an international group heading to the center of the coronavirus outbreak in China said they still have no answer on whether they’ll be allowed into the country.U.S. officials have said they’ve offered for weeks to send front-line disease experts to China to study the outbreak, which originated in the city of Wuhan, and consult with colleagues there on how to stop it.“We haven’t been invited yet,” Nancy Messonnier, director of the CDC’s National Center for Immunization and Respiratory Diseases, told reporters Wednesday.Read the full story here.Mobile World Congress Is Canceled (1:45 p.m. NY)Mobile World Congress, the premier mobile-industry conference scheduled this month in Spain, was canceled over concerns about the spread of the coronavirus.“With due regard to the safe and healthy environment in Barcelona and the host country today, the GSMA has canceled MWC Barcelona 2020 because the global concern regarding the coronavirus outbreak, travel concern and other circumstances, make it impossible for the GSMA to hold the event” John Hoffman, the chief executive officer of conference organizer GSMA Ltd., said in a statement to Bloomberg News.Intel Corp., MediaTek Inc., AT&T Inc., Cisco Systems Inc. and Sprint Corp. joined Ericsson AB, Sony Corp. and others earlier this week in canceling plans to attend MWC Barcelona later this month.CDC Says Warm Weather May Not Slow Outbreak (1:06 p.m. NY)It’s too early to know if warm spring weather that typically heralds the end of cold and flu season will also slow the coronavirus, said a top official from the U.S. Centers for Disease Control and Prevention.Nancy Messonnier, director of the CDC’s National Center for Immunization and Respiratory Diseases, said Wednesday that she hopes “it will go down as the weather warms up, but it’s premature to assume that.”Messonnier’s remarks Wednesday run counter to a theory put forward by President Donald Trump that heat would stop the new coronavirus.“The heat, generally speaking, kills this kind of virus,” Trump said Monday at the White House. “A lot of people think that goes away in April as the heat comes in.” At a campaign rally this week, he went further, according to a CNN report on his remarks, saying, “in theory when it gets a little warmer it miraculously goes away.”During a call with reporters Wednesday Messonnier said, “I would caution against over-interpreting that hypothesis.”The theory that the coronavirus will slow down when warm weather sets in is mostly based on the fact that other respiratory viruses such as influenza exhibit seasonal patterns, not specific data about this new virus, she said.More from the CDC press briefing:CDC officials haven’t yet been allowed into China or been given direct access to raw data on the epidemic.Some states conducting tests using CDC coronavirus test kits are getting inconclusive results. The CDC said it was working to resolve the problem.CDC is optimistic that lower case counts coming from China in the last few days mean that the country’s quarantine is working, but that it’s “too soon to say that for sure,” Messonnier said.Fed Chair Says Too Early to Know Virus Impact (11:15 a.m. NY)Federal Reserve Chairman Jerome Powell said it will take time to see the impact of the coronavirus outbreak on the U.S. economy.“It’s too uncertain to even speculate” Powell told the Senate Banking Committee on Wednesday. “We’ll be looking at the economic data.”Carnival Sees Material Impact on Results (9:28 a.m. NY)Carnival Corp. said it foresees a slowdown in global bookings and an increase in canceled voyages that will will have a material impact on financial results that wasn’t anticipated because of the coronavirus oubreak.“As a result of coronavirus, the company believes the impact on its global bookings and canceled voyages will have a material impact on its financial results which was not anticipated in the company’s previous 2020 earnings guidance,” the Miami-based cruise ship operator said in a statement Wednesday.The company said it was unable to determine the full financial impact on the current fiscal year.Read the full story hereMobile Conference Organizer Seeks Advice (8:10 a.m. NY)The organizer of MWC Barcelona, the wireless industry’s top annual event, said it has implemented additional health measures and will continue to seek medical advice as it monitors the situation. “This includes regularly meeting with global and Spanish health experts as well as our partners to ensure the wellbeing of attendees,” the GSMA said in a statement.The event is threatened by the withdrawal of some of the biggest telecom companies. The organizer could announce its cancellation as early as Wednesday, people familiar with the matter said earlier. MWC is due to run from Feb. 24 to Feb. 27, drawing around 100,000 people.Germany Faces Recession Risk, Deutsche Bank Says (7:45 a.m. NY)Germany could be on the verge of recession as the coronavirus outbreak exacerbates the nation’s industrial slump, according to Deutsche Bank.The lender now expects a slight contraction in the fourth quarter, and it cast doubt on the prospect of any rebound at the start of 2020. German GDP figures are due to be published on Friday.Chinese Grand Prix Postponed (7:17 a.m. NY)The 2020 Chinese Grand Prix, scheduled for April 17-19, has been postponed as a result of the novel coronavirus outbreak, organizers confirmed.Formula 1 and the FIA will study potential alternative dates later in the year.OPEC Slashes Oil Demand Forecast (7:05 a.m. NY)OPEC cut forecasts for global oil demand as the coronavirus hits fuel use in China, leaving the group facing a renewed glut despite its recent production cuts.The cartel reduced projections for demand growth in the first quarter by 440,000 barrels a day, or about a third, in its monthly report.Cruise Ship Heads to Cambodia (6:50 a.m. NY)The Westerdam luxury cruise liner is now sailing to Sihanoukville, Cambodia. It is due to arrive Feb. 13 and will remain in port for several days. Guests will be able to go ashore.Earlier, Thailand said it would consider helping any sick person aboard but stood by its decision to bar entry, as the ordeal continued for the 2,257 passengers and crew looking to disembark.The Westerdam, which is facing the risk of running low on food, has also been refused entry by Taiwan, Japan, the Philippines and Guam. Carnival Corp.’s Holland America Line, the operator of the ship, has said there’s no reason to believe there are any coronavirus cases on board.Hong Kong Sevens to Be Postponed, TVB Says (6:21 a.m. NY)The Hong Kong Sevens, an annual international rugby tournament that has been running since 1976, is set to be postponed, local broadcaster TVB reported. It was set to start in April.A formal announcement will be made this week.JLR to Extend Shutdown of China Manufacturing: ET (6:20a.m. NY)Tata Motors Ltd.‘s Jaguar Land Rover unit has told its vendor network that the shutdown of its manufacturing operations in China would be extended till Feb. 17, the Economic Times reported.UOB Allocates S$3 Billion in Liquidity Relief (6:58 p.m. HK)United Overseas Bank has allocated S$3 billion ($2.2 billion) of “relief assistance” to Singapore companies aimed at addressing near-term liquidity as the coronavirus impacts economic activity.The bank is offering financing liquidity against mortgages, and will extend working capital financing of as much as S$5 million for as long as one year.ECB’s Lane Sees ‘Pretty Serious’ Short-Term Hit (6:42 p.m. HK)European Central Bank Chief Economist Philip Lane warned that the outbreak could have a “pretty serious short-term hit” to the economy as spending plans are postponed or canceled. He also foresees a bounceback though, with the full-year impact “relatively minor.”It’s a tricky time for the euro zone. Figures on Wednesday showed industrial output slumped the most in almost four years in December, and a January recovery now looks in doubt.Hong Kong Landlords Start to Slash Retail Rents (5:53 p.m. HK)Sun Hung Kai Properties Ltd., the city’s largest developer by market value, will reduce rents for February by 30% to as much as 50% for some of its mall tenants to help them ride out the impact from the virus. Wharf Real Estate Investment Co. announced a similar move for its Harbour City shopping center, Apple Daily reported.Hong Kong’s usually booming property market has virtually ground to a halt. Just 13 homes were sold in the first three weekends after Chinese New Year at the city’s 10 largest housing estates, according to Centaline Property Agency Ltd. data.China’s Battery Storage Capacity Could Drop (5:13 p.m.)China’s battery storage production capacity may fall by as much as 10% to 237 gigawatt-hour this year compared with a pre-coronavirus forecast, Wood Mackenzie said in a note. Tight battery cell supply could slow down the cost decline of EV manufacturing and energy storage systems.China Should Target Bigger Fiscal Deficit: Ex-Official (4:48 p.m. HK)The country’s fiscal deficit should exceed usual 3% of GDP this year to help curb impact of the coronavirus outbreak on the economy, according to an article by Huang Qifan, a former legislator and official.BMW to Reopen Chinese Factories Next Week (4:33 p.m. HK)BMW plans to reopen its Chinese factories on Feb. 17. The carmaker said it was too early to know full effect of the virus.Taiwan Cuts 2020 GDP Forecast (4:28 p.m. HK)Taiwan lowered its estimate for full-year growth and officials said the coronavirus outbreak was set to diminish global trade this year. Gross domestic product will likely expand 2.37% this year, the statistics bureau said, compared to a previous government forecast of 2.72%.Separately, Sweden’s Riksbank said the coronavirus would likely reduce global growth in the short term, but it was difficult to fully assess the economic consequences.DBS Evacuates 300 Employees in Singapore (2:25 p.m. HK)DBS Group Holdings Ltd. evacuated 300 employees from an office floor in the heart of Singapore’s financial district after one of its workers tested positive for the coronavirus.Southeast Asia’s biggest bank has told the staff members on Level 43 at Marina Bay Financial Centre Tower 3 to work from home for the time being, the company said in a statement. The number of evacuees was given in a memo seen by Bloomberg earlier and confirmed by the bank.The coronavirus had already been detected in Singapore’s financial district earlier this week, prompting some companies to send workers home and temperature screening checkpoints to be set up at the entrances of several towers. A worker at an unnamed firm in Marina Bay Financial Centre Tower 1 was confirmed as being infected with the virus over the weekend.Singapore last week raised its disease response level to the same grade used during the SARS epidemic, as it braced for what Prime Minister Lee Hsien Loong said was a “major test for our nation.” Singapore has at least 47 confirmed cases of coronavirus.Early Virus Data Existed Weeks Before Public Release (11:32 a.m. HK)Preliminary genetic sequence data indicating the presence of a SARS-like virus in central China were known about two weeks before key information was publicly released, scientists said.In a commentary piece published Tuesday in the Lancet medical journal, scientists, including members of the World Health Organization’s emergency committee, said insufficient attention was paid to information doctors had gathered about the genetic sequence of the novel coronavirus.Chinese Company Says It Can Make Gilead’s Virus Drug (11:18 a.m. HK)A Chinese drugmaker said it has started mass-producing an experimental drug from Gilead Sciences Inc. that has the potential to fight the novel coronavirus, as China accelerates its effort to find a treatment for the widening outbreak.Suzhou-based BrightGene Bio-Medical Technology Co. said it has developed the technology to synthesize the active pharmaceutical ingredients of remdesivir, Gilead’s drug that is a leading candidate to treat the highly-infectious virus that’s killed more than 1,000 people. The drug isn’t licensed or approved anywhere in the world yet.While BrightGene said that it intends to license the drug from Gilead, its move to start manufacturing at this early stage is highly unusual and a potential infringement of the American company’s intellectual property. It comes a week after Chinese researchers filed an application to patent the drug to treat the new coronavirus.Singapore Not Ruling Out More Stringent Measures (10:50 a.m. HK)Singapore is not ruling out more stringent measures to tackle the coronavirus outbreak if the situation worsens, according to Minister for National Development Lawrence Wong.Singapore is preparing a strong package in the upcoming budget to help companies and individuals manage the economic impacts of the virus, Wong said in a Bloomberg TV interview. Singapore can implement additional measures to contain the spread of the virus without raising the national response level to red, he said.China Death Toll Rises to 1,113 (10:08 a.m. HK)China said the death toll from the coronavirus outbreak rose to 1,113 as of Feb. 11, with 97 additional fatalities reported. Some 1,068 of those deaths have occurred in Hubei, the province at the center of the coronavirus outbreak.Confirmed cases of the disease in mainland China rose to 44,653, according to a statement from the National Health Commission.Hubei reported 1,638 additional cases, the lowest daily level this month. That’s an encouraging sign for health experts looking for when the outbreak peaks. Also, the number of suspected cases as of Feb. 11 was 16,067, down from 21,675 the previous day.Two deaths have been reported outside mainland China, one in Hong Kong and the other in the Philippines.China Supports Merger of Airlines Amid Outbreak (10:01 a.m. HK)China’s Civil Aviation Administration said it will support the restructuring of airlines to ease the impact from the coronavirus outbreak. The administration will also work with the Ministry of Foreign Affairs in urging some countries to continue international flights with China.The coronavirus outbreak has disrupted flights to and from China, one of the world’s busiest travel markets, as airlines around the globe halt service.Xi Vows China Will Meet Economic Goals, Defeat Virus (9:10 a.m. HK)President Xi Jinping vowed that China would meet its economic and social development goals while winning the battle against the deadly coronavirus.“We have the ability and confidence not only to defeat the epidemic, but also to accomplish the set goals and tasks for economic and social development,” he told Indonesian leader Joko Widodo in a phone call Tuesday, according to the official Xinhua news agency. “I believe China will be more prosperous after overcoming this epidemic.”China Ag Purchases May Be Less Than Hoped: Official (8:42 a.m. HK)China’s agricultural purchases from the U.S. under the first phase of a trade deal may not be as large as the Trump administration had hoped due to the coronavirus, said White House National Security Advisor Robert O’Brien.“It could have an impact on how big, at least in this current year, the purchases are,” O’Brien said at an Atlantic Council event Tuesday in Washington. He also said American doctors are still not being let into China to deal with the outbreak.Japan Reports 39 More Cases Aboard Cruise Ship (7:54 a.m. HK)Japan’s Health Ministry confirmed an additional 39 cases of the novel coronavirus on a cruise ship in Yokohama, bringing the total number of infections from the quarantined vessel to 174.Defense Minister Taro Kono tweeted that a quarantine officer from the health ministry also tested positive for the virus. Carnival Corp.’s Diamond Princess cruise ship has become the biggest center of infection of any place outside of China.U.S. Raises Travel Advisory for Hong Kong (3:20 p.m. NY)The U.S. State Department raised its travel advisory for Hong Kong to level 2, which means travelers should exercise increased caution.“The Hong Kong government has reported cases of the novel coronavirus in its special administrative region, has upgraded its response level to emergency, its highest response level, and is taking other steps to manage the novel coronavirus outbreak,” the department said.Last month, the U.S. raised the advisory for mainland China to level 4, the highest designation, which means do not travel.\--With assistance from K. Oanh Ha, Li Liu, Josh Wingrove, Emi Nobuhiro, Michael Heath, Karen Leigh, Dong Lyu, James Mayger, Sam Kim, Jon Herskovitz, Chanyaporn Chanjaroen, Paul Gordon, Morwenna Coniam, Kati Pohjanpalo, John Martens, Timothy Annett, Nate Lanxon, Saleha Mohsin and Nikos Chrysoloras.To contact Bloomberg News staff for this story: Michelle Fay Cortez in Minneapolis at;Isabel Reynolds in Tokyo at;Jason Gale in Melbourne at;Robert Langreth in New York at rlangreth@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at, ;Rachel Chang at, ;Adveith Nair at, Mark SchoifetFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Chinese Firm Makes Gilead Drug in Virus Fight, Raising IP Fears

    Chinese Firm Makes Gilead Drug in Virus Fight, Raising IP Fears

    (Bloomberg) -- A Chinese drugmaker said it has started mass-producing an experimental treatment from Gilead Sciences Inc. that has shown potential to fight the novel coronavirus, adding to concerns that the U.S. pharma company is losing patent control in China’s accelerating effort to fight the outbreak.Suzhou-based BrightGene Bio-Medical Technology Co. said it has developed technology to synthesize the active pharmaceutical ingredients of Gilead’s remdesivir. A leading candidate to treat the virus that’s killed more than 1,000 people, the drug isn’t licensed or approved anywhere in the world. BrightGene rose 20% Wednesday in Shanghai.China Wants to Patent Gilead’s Experimental Coronavirus Drug (3)While BrightGene said it intends to license the drug from Gilead, its move to start manufacturing at this early stage is highly unusual and a potential challenge to the U.S. company’s intellectual property. Last week, Chinese researchers at the Wuhan Institute of Virology filed an application in China to patent the drug, which was developed for Ebola, to treat the new coronavirus.The aggressive moves to make and assume control of Gilead’s drug could revive concerns about the protection of intellectual property rights in China, long an area of concern for U.S. and European pharma companies, tech giants and others. The country has been making strides in the area as it nurtures a domestic industry based on innovative, patented drugs as companies develop their businesses in China.China has a difficult balance to strike, as it tries to speed development of one of the most promising potential treatments for an illness that has infected almost 45,000 people without undermining those commitments.Compulsory LicenseDespite the steps by BrightGene and Wuhan researchers, the central government has so far stopped short of seeking a “compulsory license,” which lets nations override drug patents in national emergencies. The hesitation to invoke that clause may be part of its continued efforts to demonstrate greater respect for companies’ rights.“In general, production constitutes a patent infringement, but there’s an exception if the production is intended only for regulatory approval and not for sale in the market,” said Wang Yanyu, a Beijing-based partner specializing in intellectual property at AllBright Law Offices.Gilead said it’s aware of BrightGene’s announcement and that it remains “focused on rapidly determining the potential for remdesivir to treat COVID-19,” the name given by the World Health Organization to the new syndrome. The company has said that any discussion of licensing the investigational drug is “premature.”Because of its experience with drugs like remdesivir, BrightGene said, it’s been able to get ready for production quickly.Large areas of China have been locked down by the coronavirus epidemic, while other countries are barring entry to some travelers. Gilead’s drug is seen as a potential breakthrough in the fight against the disease since it showed signs of helping patients in the U.S.761 PatientsChinese researchers are now testing the drug on 761 patients in clinical trials in Wuhan.BrightGene said that before selling the drug, it will have to license it from Gilead, conduct clinical trials and obtain approval. Its technology to make remdesivir may not be of much value if the drug fails to produce results from clinical trials, or if the epidemic comes under control soon, it said.Last week, Gilead said it has patented remdesivir in China, including filing applications for use on coronaviruses. The company also said that it is working with Chinese, U.S. and World Health Organization officials to rapidly determine whether the drug can be used to treat the virus.\--With assistance from John Lauerman.To contact Bloomberg News staff for this story: Dong Lyu in Beijing at dlyu3@bloomberg.netTo contact the editors responsible for this story: Rachel Chang at, Eric Pfanner, Thomas MulierFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Can Biotech ETFs Gain on Mixed Q4 Earnings Results?

    Can Biotech ETFs Gain on Mixed Q4 Earnings Results?

    Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.

  • Coronavirus update: 1,018 deaths, a new case in San Diego, 195 evacuees expected to leave quarantine

    Coronavirus update: 1,018 deaths, a new case in San Diego, 195 evacuees expected to leave quarantine

    A passenger who was repatriated from Wuhan, China, on a U.S. flight and has been in quarantine in San Diego is the latest individual in the U.S. to test positive for the coronavirus, according to media reports.

  • Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance

    Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance

    The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.

  • Benzinga

    The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...

  • New Strong Sell Stocks for February 10th

    New Strong Sell Stocks for February 10th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Financial Times

    Coronavirus sparks hectic trading in search of treatment

    Investors are bidding up companies trying to alleviate the coronavirus outbreak, from biotechs working on treatments and vaccines to telemedicine companies catering for the sick stuck at home. “There has been an incredible amount of interest in the biotech industry in the wake of the coronavirus,” said Thomas Hayes, chairman of Great Hill Capital, the New York-based hedge fund.


    Prudential Financial, Gilead, and 3M Raised Dividends Last Week

    Biotech company Gilead Sciences is increasing its quarterly dividend to 68 cents a share, an 8% boost, and Prudential declared a 10% dividend increase.

  • As coronavirus infections surge, Bay Area offers a possible drug, diagnostic and advice
    American City Business Journals

    As coronavirus infections surge, Bay Area offers a possible drug, diagnostic and advice

    Why time and patents could stand in the way of Bay Area companies working on ways to block the spread of the deadly Wuhan coronavirus.

  • Coronavirus update: Business impact widens as China fights to get infections under control
    Yahoo Finance

    Coronavirus update: Business impact widens as China fights to get infections under control

    China’s deadly coronavirus outbreak continues to threaten multi-national companies, as a range of businesses from leisure to retail suffer from the outbreak’s after-effects.


    ‘No Glitches’ in Early Effort for Coronavirus Vaccine, NIH Says. Moderna Stock Is Flying.

    The biotech company Moderna’s effort to develop a vaccine for the coronavirus is proceeding with “no glitches so far,” an official with the National Institutes of Health said.

  • 4 Internet Stocks to Buy That Are Surging Higher

    4 Internet Stocks to Buy That Are Surging Higher

    Currently, U.S. equities like internet stocks are extending to the upside, as investors act like the coronavirus never happened.This comes as the pandemic remains largely relegated to China, and Gilead (NASDAQ:GILD) works on an anti-viral treatment that is headed to human trials. Additionally, the end of the impeachment trial against President Donald Trump and word China will cut the tariff rate on $75 billion worth of U.S. imports by 50% is lifting spirits up and down the Street.As a result, a number of internet stocks are perking up nicely.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSome of these companies have recently reported their earnings, and shareholders are feeling the positive and negative effects. However, these four names are worth a look if investors are looking to add some internet stocks to their portfolio. * 5 Cloud Stocks to Buy for Big Gains in 2020 With all of that in mind, let's take a closer look. Internet Stocks to Buy: Twitter (TWTR) Click to Enlarge Source: Chart courtesy of StockCharts.comTwitter (NYSE:TWTR) just reported earnings that came up a little short of the consensus estimate. However, investors were impressed by the company's monetizable daily active users (mDAU) growth of 21%. In turn, this rise helped boost the stock more than 13% that day.Furthermore, this rise allowed TWTR stock to cross over the 200-day moving average and return to levels not seen since October. Additionally, the company reported a revenues increase of 10.8% year-over-year to just over $1 billion.Twitter continues to play a central role in the run-up to the U.S. presidential election later this year. With that, the company announced in a blog post earlier this week that it will crack down on "synthetic and manipulated media" as fears over "deep fakes" continue to grow.Overall, expect a wild ride higher in the months to come. This surge will arise as the campaign trail heats up, and Twitter's role as the repository of hot takes and instant reporting grows more important. Therefore, now may be the time to add TWTR to your list of internet stocks. Amazon (AMZN) Click to Enlarge Source: Chart courtesy of StockCharts.comAmazon (NASDAQ:AMZN) is consolidating its push to new record highs, eclipsing the prior highs set in late 2018 and the summer of 2019. Investors are continuing to enjoy upward momentum from the strong quarterly results reported at the end of January, with North American sales up 22% and advertising revenue up 41% from the prior year.In turn, RBC Capital analyst Mark Mahaney responded by raising his price target to $2,700 following the first top- and bottom-line beat by the company since the first quarter of 2018.Additionally, Oppenheimer analyst Jason Helfstein also raised his price target thanks to better-than-expected profit margins. This move comes despite the investment spending necessary to roll out 1-day and same-day delivery options to users. Amazon also noted in their earning report that Prime subscriptions are up to an impressive 150 million. * 5 Total Yield Dividend Stocks That Offer Attractive Returns With all of that in mind, AMZN stock is climbing higher and higher -- making it a prime addition to the best internet stocks to buy. Netflix (NFLX) Click to Enlarge Source: Chart courtesy of StockCharts.comShares of Netflix (NASDAQ:NFLX) stock have risen to test the prior high set back in July, returning to the upper end of a three-year consolation range.The company reported better-than-expected earnings for the fourth quarter thanks to a doubling of operating income YoY. Subscriber numbers were a little soft, however, as the streaming wars intensify with Apple (NASDAQ:AAPL) and Disney (NYSE:DIS) pushing in on the turf it used to enjoy alone.Based on their Q1 guidance for 2020, it seems that Netflix is expecting lower figures in revenue and global streaming memberships. However, analysts at Citigroup recently raised their outlook on the ongoing trend of consumer cord cutting.In short, NFLX is just another great part of the internet stocks to add to your portfolio. eBay (EBAY) Click to Enlarge Source: Chart courtesy of StockCharts.comEBay (NASDAQ:EBAY) shares are surging higher, enjoying a 20% rise off of their recent low. This rise comes after Intercontinental Exchange (NYSE:ICE) offered to the buy the company for more than $30 billion.However, ICE -- the owner of the New York Stock Exchange -- has seen its shares sink in the wake of the news as the deal doesn't appear on the surface to contain a lot of synergies. Sure, both eBay and the NYSE involves bidding to match buyers and sellers. But buying stocks within microseconds is a lot different than buying trinkets and old movies on eBay.So, it's hard to see how the expertise crosses over.The news came as a welcome change of subject for investors after Canaccord Genuity analyst Michael Graham dropped his target price for eBay stock at the end of January occurred because of worries about margin headwinds and the long-term outlook. Unfortunately, the good vibes were short lived as ICE backed away from the deal.Still, this member of the internet stocks has some technical momentum now -- which should bring in program buying and potentially attract buying interest from other strategic buyers.As of this writing, William Roth did not hold any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Utility Stocks to Buy That Offer Juicy Dividends * 10 Gold and Silver Stocks to Profit Off 2020's Fear Trade * 3 Top Companies That Should Be More Careful With Your Data The post 4 Internet Stocks to Buy That Are Surging Higher appeared first on InvestorPlace.

  • Thomson Reuters StreetEvents

    Edited Transcript of GILD earnings conference call or presentation 4-Feb-20 9:30pm GMT

    Q4 2019 Gilead Sciences Inc Earnings Call

  • The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences

    The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences

    The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences

  • 3 Big Stock Charts for Friday: Barrick Gold, Gilead Sciences, and Cloudflare

    3 Big Stock Charts for Friday: Barrick Gold, Gilead Sciences, and Cloudflare

    Optimism has returned to the equity markets in a hurry. U.S. stocks moved higher for a fourth consecutive session Thursday. The S&P 500 now has risen almost 4% this week alone. The NASDAQ Composite is up almost 5%.Source: Shutterstock Even in this confident market, however, a few stocks have been left behind. Friday's big stock charts feature three of those names. * 7 Biotech Stocks to Buy That Could Beat the Coronavirus These aren't stocks that investors have dumped, necessarily. Rather all three stocks have been mostly stuck, either in recent sessions or in recent months. The sideways trading is somewhat interesting in a market that has been much more volatile so far in 2020. And in all three cases, that sideways trading seems unlikely to last.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Barrick Gold (GOLD)Source: Provided by Finviz The news certainly has improved for Barrick Gold (NYSE:GOLD). GOLD stock has rallied over 50% from May lows. The stock finally has taken advantage of higher gold prices, long a problem for Barrick and the sector as a whole.Ahead of fourth quarter earnings on Wednesday, however, investors have taken a 'wait and see' approach, as the first of Monday's big stock charts shows. So it may be gold itself that determines the near-term move for GOLD stock: * GOLD stock has established a narrowing wedge pattern. That pattern often means that the stock makes an accelerated move in whichever direction it exits the wedge. Right now, the bias probably is bullish. Both GOLD stock and the gold price have drifted higher since November. A small rally here would exit the wedge, break through recent resistance, and potentially augur an upside breakout. * But for that to happen, gold prices need to cooperate. The Q4 earnings report might move the stock, but most commodity producers don't necessarily see huge one-day swings. The options market, for instance, projects such a 4% move in Barrick stock between now and next Friday. A big move in gold could have a big effect, however, and technicals for the yellow metal do look somewhat promising. * The reliance on gold prices does make GOLD stock intriguing at the moment. Presumably, moderating coronavirus fears should be good for stocks -- and bad for gold, which could pressure shares. But Barrick, per its chief executive officer, may be looking to add more copper assets to its portfolio, even as the company denies rumors of a tie-up with copper giant Freeport-McMoran (NYSE:FCX). With so much going on, it does make sense that GOLD remains in a holding pattern, but I'd expect movement at some point soon, even if earnings aren't the catalyst. Gilead Sciences (GILD)Source: Provided by Finviz As the second of our big stock charts shows, Gilead Sciences (NASDAQ:GILD) has been trading sideways all the way back to late 2018. Shares have bounced of late, but Thursday's retreat does look somewhat worrisome: * On its face, the 3.55% pop on Thursday seems like good news. GILD challenged resistance and actually set a six-month closing high in the process. But intraday trading looks a bit weak: shares sold off after a big morning rally, and settled back toward long-term resistance. For over a year now, investors have simply balked at paying more than $70 a share for Gilead stock, and they did so again on Thursday. * Admittedly, shares have built momentum of late and could continue to do so. Gilead's remdesivir is being tested in China on an experimental basis as a coronavirus treatment. But Gilead also saw some negative news this week, with a disappointing fourth quarter report and soft guidance for 2020. * Fundamentally, it does seem like resistance may hold. GILD stock does look cheap, and a 3.7% dividend yield helps the case. But the company's own guidance suggests a double-digit decline in earnings per share in 2020; the stock probably should be cheap. * And so GILD stock needs a catalyst -- and remdesivir might be it. If it's not, however, a return to the low end of the range hardly seems unlikely. Cloudflare (NET)Source: Provided by Finviz Unlike most 2019 initial public offerings, security provider Cloudflare (NYSE:NET) has seen quiet trading out of the gate. That stands in stark contrast to the likes of Uber (NYSE:UBER) and Lyft (NASDAQ:LYFT), which fell sharply almost immediately, and Beyond Meat (NASDAQ:BYND), which at one point had risen over 800% from its IPO price.Here, too, investors are in 'wait and see' mode. That might change on Thursday afternoon: * Early trading in NET stock has established a textbook wedge pattern, with the range continuing to narrow of late. Somewhat incredibly, given that Cloudflare is an unprofitable, high-growth name in a crowded field, shares haven't closed below $17 or above $19 since late December. * Fourth quarter earnings arrive after the close on Thursday and should lead to some movement. NET stock did trade basically flat after the Q3 report in November: shares gained 1.45% the following day. But 2020 guidance should be included with the release, and will be closely watched. * With NET trading at about 18x 2019 revenue even backing out its cash balance, sideways trading isn't going to last forever. A strong outlook for 2020 drives fundamental upside, perhaps leading NET to join the ranks of 'hot' growth stocks. Technically, an upside wedge exit would suggest a potential breakout, and establish near-term moving averages as support. Of course, the converse is true as well. At 18x sales, a soft outlook is not priced in. And there's a lot of whitespace on the chart to the downside if NET stock stumbles next week.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Utility Stocks to Buy That Offer Juicy Dividends * 10 Gold and Silver Stocks to Profit Off 2020's Fear Trade * 3 Top Companies That Should Be More Careful With Your Data The post 3 Big Stock Charts for Friday: Barrick Gold, Gilead Sciences, and Cloudflare appeared first on InvestorPlace.

  • Can Biotech ETFs Continue to Soar in 2020?

    Can Biotech ETFs Continue to Soar in 2020?

    We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.